As novel therapies such as selective estrogen receptor degraders and PI3K inhibitors are being developed and are entering clinical practice, our results highlight the pivotal role of ctDNA NGS in describing tumor evolution under treatment pressure and optimizing both clinical decision making and future drug development. Here, ESR1 is linked to neoplasm.